Carcinoma, Non-Small-Cell Lung

Showing NaN - NaN of 44

STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS

NSCLC, NSCLC, Carcinoma, Bronchogenic Trial in Worldwide (Furmonertinib)

Recruiting
  • Non-Small Cell Lung Cancer
  • +14 more
  • Glendale, California
  • +12 more
Feb 2, 2023

NSCLC Trial in Worldwide (Amivantamab, Pemetrexed, Carboplatin)

Active, not recruiting
  • Carcinoma, Non-Small-Cell Lung
  • Duarte, California
  • +228 more
Jan 31, 2023

NSCLC Trial in Worldwide (TAK-788)

Recruiting
  • Carcinoma, Non-Small-Cell Lung
  • Birmingham, Alabama
  • +56 more
Jan 23, 2023

Ovarian Tumors, Endometrial Tumors, NSCLC Trial in United Kingdom, United States (SGN-ALPV)

Recruiting
  • Ovarian Neoplasms
  • +5 more
  • Fresno, California
  • +10 more
Jan 20, 2023

NSCLC Trial in Worldwide (Alectnib, Cisplatin, Vinorelbine)

Active, not recruiting
  • Carcinoma, Non-Small-Cell Lung
  • Chicago, Illinois
  • +140 more
Jan 20, 2023

NSCLC Trial in Worldwide (Sasanlimab Prefilled syringe, Encorafenib, Binimetinib)

Active, not recruiting
  • Carcinoma, Non-Small-Cell Lung
  • Sasanlimab Prefilled syringe
  • +5 more
  • Duarte, California
  • +96 more
Jan 18, 2023

Tumors, NSCLC Trial in Worldwide (BI 754111, BI 754091)

Active, not recruiting
  • Neoplasms
  • Carcinoma, Non-Small-Cell Lung
  • BI 754111
  • BI 754091
  • Miami, Florida
  • +14 more
Jan 9, 2023

NSCLC Trial in Worldwide (INC280 (capmatinib))

Active, not recruiting
  • Carcinoma, Non-Small-Cell Lung
  • INC280 (capmatinib)
  • Long Beach, California
  • +95 more
Dec 29, 2022

NSCLC Trial in Worldwide (Selpercatinib, Placebo)

Recruiting
  • Carcinoma, Non-Small-Cell Lung
  • Santa Monica, California
  • +206 more
Dec 27, 2022

NSCLC Trial in Worldwide (Durvalumab, Placebo, Osimertinib (single-arm, open-label))

Recruiting
  • Carcinoma, Non-Small-Cell Lung
  • Tuscaloosa, Alabama
  • +260 more
Dec 16, 2022

RET-altered Non Small Cell Lung Cancer, Medullary Thyroid Cancer, RET-altered Papillary Thyroid Cancer Trial in Worldwide

Active, not recruiting
  • RET-altered Non Small Cell Lung Cancer
  • +39 more
  • pralsetinib (BLU-667)
  • Phoenix, Arizona
  • +65 more
Nov 10, 2022

Lung Tumors, NSCLC Trial in Worldwide (biological, drug, radiation)

Recruiting
  • Lung Neoplasms
  • Carcinoma, Non-Small-Cell Lung
  • Pembrolizumab
  • +9 more
  • Mobile, Alabama
  • +194 more
Aug 18, 2022

Carcinoma, Non-small-Cell Lung Trial in Worldwide (Amivantamab, Lazertinib, Carboplatin)

Not yet recruiting
  • Carcinoma, Non-small-Cell Lung
  • Westwood, Kansas
  • +47 more
Aug 17, 2022

NSCLC Trial in Worldwide (Amivantamab, Osimertinib, Lazertinib)

Active, not recruiting
  • Carcinoma, Non-Small-Cell Lung
  • Goodyear, Arizona
  • +266 more
Aug 17, 2022

NSCLC Trial in Worldwide (Lazertinib, Amivantamab, Pemetrexed)

Recruiting
  • Carcinoma, Non-Small-Cell Lung
  • Phoenix, Arizona
  • +303 more
Aug 17, 2022

Uterine Tumors, Uterine Cervical Tumors, Biliary Tract Tumors Trial in Worldwide (tucatinib, trastuzumab, fulvestrant)

Recruiting
  • Uterine Neoplasms
  • +5 more
  • Goodyear, Arizona
  • +63 more
Aug 15, 2022

Urinary Bladder Tumors, Colorectal Cancer, NSCLC Trial in Worldwide (AZD8853, Zirconium-89 crefmirlimab berdoxam)

Recruiting
  • Urinary Bladder Neoplasms
  • +2 more
  • AZD8853
  • Zirconium-89 crefmirlimab berdoxam
  • New Haven, Connecticut
  • +14 more
Aug 8, 2022

NSCLC Trial in Worldwide (Capmatinib, Amivantamab)

Not yet recruiting
  • Carcinoma, Non-Small-Cell Lung
  • Orange, California
  • +40 more
Aug 3, 2022

NSCLC Trial in Worldwide (Atezolizumab)

Completed
  • Carcinoma, Non-Small-Cell Lung
  • Caba, Argentina
  • +111 more
May 25, 2022

NSCLC Trial in Worldwide (nab-paclitaxel IV, CC-486, Duravalumab)

Active, not recruiting
  • Carcinoma, Non-Small-Cell Lung
  • nab-paclitaxel IV
  • +2 more
  • San Francisco, California
  • +33 more
Jan 24, 2022

NSCLC Trial in Worldwide (LY2875358, Erlotinib)

Active, not recruiting
  • Carcinoma, Non-Small-Cell Lung
  • Herlev, Denmark
  • +41 more
Sep 2, 2021

NSCLC Trial in Worldwide (Avelumab, Docetaxel)

Completed
  • Carcinoma, Non-Small-Cell Lung
  • Tuscaloosa, Alabama
  • +259 more
Jul 20, 2020

NSCLC Trial in Worldwide (Tislelizumab, Concurrent chemoradiotherapy (cCRT), Placebo)

Terminated
  • Carcinoma, Non-Small-Cell Lung
  • Los Angeles, California
  • +163 more
Jun 26, 2020